The Pharmacological Guide to Metformin

Natalie Lajoie (Editor)

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$160.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Almost six decades after its discovery, metformin still remains the gold standard drug for the management of type 2 diabetes mellitus, owing to its euglycemic property and cost-effectiveness. It is the most commonly prescribed and utilized oral antidiabetic drug worldwide. However, no two persons with the same phenotypical characteristics, such as age, gender, body weight and others, tend to respond similarly to equivalent doses of metformin. As such, The Pharmacological Guide to Metformin first focuses on the various genetic polymorphisms that influence the therapeutic effects of metformin.

Physicochemical, pharmacological, and pharmacokinetic properties of metformin will also be reviewed.

The side effects of this drug can be dangerous. Metformin-induced lactic acidosis is a lethal disorder. The first significant deviation is gastrointestinal tract involvement. Common infection or the effect of metformin itself causes vomiting and diarrhea, with subsequent hypovolemia causing pre-renal acute kidney injury, which in turn raises metformin levels up to toxic values. Development of kidney failure is often unexpected and fast.

Following this, the authors explore the differences between healthy and cancer cells and how this may influence the metformin effect on these cells.

In conclusion, the molecular mechanisms underlying the anticancer effects of metformin in breast and ovarian cancers are summarized, and the potential anticancer applications of metformin-based combinatorial chemotherapy are discussed.
(Imprint: Nova Medicine and Health)

Preface

Chapter 1. The Pharmacogenetics of Metformin
(Gerard Marshall Raj and Saranya Vilvanathan, Sri Venkateshwaraa Medical College Hospital and Research Centre, Puducherry, India, and Medical University of the Americas, Charlestown, Nevis, Saint Kitts and Nevis, West Indies)

Chapter 2. Physicochemical and Pharmacokinetic Properties of Metformin Hydrochloride
(Selma Sahin, PhD, and Tugba Gulsun, PhD, Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey)

Chapter 3. Metformin: Who Are Suitable Patients?
(Karel Kubát MD, Department of Internal Medicine, Litomerice Hospital, Litomerice, Czech Republic)

Chapter 4. Metformin Effects in Cancer Models
(André Gustavo de Oliveira, PhD, Maria Cristina C. Gomes-Marcondes, PhD, Obesity and Comorbidities Research Centre, Department of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, SP, Brazil, and others)

Chapter 5. The Therapeutic Potential of Metformin in Breast and Ovarian Cancer
(Isabella dos Santos Guimarães, Diandra Zipinotti dos Santos, Paulo CM Lyra-Junior, Ian Victor Silva and Leticia Batista Azevedo Rangel, Clinical Research Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil)

Index

You have not viewed any product yet.